Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02075515 · ClinicalTrials.gov registry record · Phase 3
Consistency, Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A in Adults ≥ 50 Years of Age
A Phase 3 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 651
- Enrollment target
NCT02075515 is a Phase 3 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 651 participants.
The verdict
NCT02075515, a Phase 3 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 651 participants
- Enrollment target
Study Summary
The purpose of this study is to demonstrate lot-to-lot consistency in terms of immunogenicity, and evaluate safety of the Herpes Zoster subunit (HZ/su) vaccine. The study is designed as a randomized, double-blind study with three parallel groups.
Interventions
- BIOLOGICAL Herpes Zoster vaccine (GSK 1437173A)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 651 participants |
| Start Date | 2014-08-13 |
| Est. Completion | 2016-04-25 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02075515
The ClinicalTrials.gov registry entry for NCT02075515 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 651 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Herpes Zoster vaccine (GSK 1437173A) is the first listed.
NCT02075515 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02075515 about?
NCT02075515 is a clinical study titled "Consistency, Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A in Adults ≥ 50 Years of Age". The purpose of this study is to demonstrate lot-to-lot consistency in terms of immunogenicity, and evaluate safety of the Herpes Zoster subunit (HZ/su) vaccine. The study is designed as a randomized, double-blind study with three parallel groups.
What is the current status of trial NCT02075515?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 651 participants. The study started on 2014-08-13. Estimated completion is 2016-04-25.
What interventions are being tested in trial NCT02075515?
The interventions under investigation include: Herpes Zoster vaccine (GSK 1437173A) (BIOLOGICAL).
Who is sponsoring clinical trial NCT02075515?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.